Elisidepsin (BioDeep_00000844033)
代谢物信息卡片
化学式: C75H124N14O16 (1476.9319264)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCC(C)CCC(=O)NC(C(C)C)C(=O)NC(C(C)O)C(=O)NC(C(C)C)C(=O)NC(C(C)C)C(=O)N1CCCC1C(=O)NC(CCCN)C(=O)NC(C(C)CC)C(=O)NC2C(OC(=O)C(NC(=O)C(=CC)NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)C(C)CC)C(C)C)CC3=CC=CC=C3)C(C)C)C
InChI: InChI=1S/C75H124N14O16/c1-20-43(15)33-34-53(91)80-54(38(5)6)68(97)87-61(46(18)90)72(101)82-56(40(9)10)69(98)83-57(41(11)12)74(103)89-36-28-32-52(89)66(95)78-50(31-27-35-76)64(93)85-59(44(16)21-2)71(100)88-62-47(19)105-75(104)58(42(13)14)84-63(92)49(23-4)77-65(94)51(37-48-29-25-24-26-30-48)79-67(96)55(39(7)8)81-70(99)60(45(17)22-3)86-73(62)102/h23-26,29-30,38-47,50-52,54-62,90H,20-22,27-28,31-37,76H2,1-19H3,(H,77,94)(H,78,95)(H,79,96)(H,80,91)(H,81,99)(H,82,101)(H,83,98)(H,84,92)(H,85,93)(H,86,102)(H,87,97)(H,88,100)/b49-23-/t43-,44-,45-,46+,47+,50-,51-,52+,54+,55+,56-,57+,58-,59+,60+,61-,62+/m0/s1
描述信息
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C259 - Antineoplastic Antibiotic
同义名列表
1 个代谢物同义名
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Sanjay Goel, Santiago Viteri, Teresa Morán, Cinthya Coronado, Jorge Luis Iglesias Dios, Bernardo Miguel-Lillo, Eva M Fernández-García, Rafael Rosell. Phase I, dose-escalating study of elisidepsin (Irvalec(®)), a plasma membrane-disrupting marine antitumor agent, in combination with erlotinib in patients with advanced malignant solid tumors.
Investigational new drugs.
2016 Feb; 34(1):75-83. doi:
10.1007/s10637-015-0305-8. [PMID: 26627080] - Mark J Ratain, David Geary, Samir D Undevia, Cinthya Coronado, Vicente Alfaro, Jorge L Iglesias, Richard L Schilsky, Bernardo Miguel-Lillo. First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors.
Investigational new drugs.
2015 Aug; 33(4):901-10. doi:
10.1007/s10637-015-0247-1. [PMID: 25947566] - José Manuel Molina-Guijarro, Carolina García, Álvaro Macías, Luis Francisco García-Fernández, Cristina Moreno, Fernando Reyes, Juan Fernando Martínez-Leal, Rogelio Fernández, Valentín Martínez, Carmen Valenzuela, M Pilar Lillo, Carlos M Galmarini. Elisidepsin Interacts Directly with Glycosylceramides in the Plasma Membrane of Tumor Cells to Induce Necrotic Cell Death.
PloS one.
2015; 10(10):e0140782. doi:
10.1371/journal.pone.0140782. [PMID: 26474061] - Anna Király, Tímea Váradi, Tímea Hajdu, Ralph Rühl, Carlos M Galmarini, János Szöllősi, Peter Nagy. Hypoxia reduces the efficiency of elisidepsin by inhibiting hydroxylation and altering the structure of lipid rafts.
Marine drugs.
2013 Dec; 11(12):4858-75. doi:
10.3390/md11124858. [PMID: 24317474] - R Salazar, R J Jones, A Oaknin, D Crawford, C Cuadra, C Hopkins, M Gil, C Coronado, A Soto-Matos, M Cullell-Young, J L Iglesias Dios, T R J Evans. A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology.
2012 Nov; 70(5):673-81. doi:
10.1007/s00280-012-1951-6. [PMID: 22926637] - A Estella-Hermoso de Mendoza, P Calvo, A Bishop, P Avilés, M J Blanco-Prieto. Comparison of pharmacokinetic profiles of PM02734 loaded lipid nanoparticles and cyclodextrins: in vitro and in vivo characterization.
Journal of biomedical nanotechnology.
2012 Aug; 8(4):703-8. doi:
10.1166/jbn.2012.1420. [PMID: 22852480] - Tímea Váradi, Janos Roszik, Duarte Lisboa, György Vereb, José Manuel Molina-Guijarro, Carlos M Galmarini, János Szöllosi, Peter Nagy. ErbB protein modifications are secondary to severe cell membrane alterations induced by elisidepsin treatment.
European journal of pharmacology.
2011 Sep; 667(1-3):91-9. doi:
10.1016/j.ejphar.2011.05.064. [PMID: 21658382] - José M Molina-Guijarro, Álvaro Macías, Carolina García, Eva Muñoz, Luis F García-Fernández, Miren David, Lucía Núñez, Juan F Martínez-Leal, Victoria Moneo, Carmen Cuevas, M Pilar Lillo, Carlos Villalobos Jorge, Carmen Valenzuela, Carlos M Galmarini. Irvalec inserts into the plasma membrane causing rapid loss of integrity and necrotic cell death in tumor cells.
PloS one.
2011 Apr; 6(4):e19042. doi:
10.1371/journal.pone.0019042. [PMID: 21556352] - Jianming Yin, Pablo Aviles, William Lee, Carl Ly, Maria Jose Guillen, Simon Munt, Carmen Cuevas, Glynn Faircloth. Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of PM02734, a novel antineoplastic agent, in dog plasma.
Rapid communications in mass spectrometry : RCM.
2006; 20(18):2735-40. doi:
10.1002/rcm.2644. [PMID: 16921565]